| Pamela Shervanick, DO | |
|
55 John A Cummings Way, Woonsocket, RI 02895-3247 | |
| (401) 235-7000 | |
| Not Available |
| Full Name | Pamela Shervanick |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 55 John A Cummings Way, Woonsocket, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942397427 | NPI | - | NPPES |
| 1529682 | Other | RI | UNITED HEALTH |
| 0000031246 | Other | RI | BLUE CROSS |
| 413214 | Other | RI | BLUE CHIP |
| 9001890 | Medicaid | RI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | DO00585 (Rhode Island) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Pamela Shervanick, DO 179 Wentworth Ave, Cranston, RI 02905-2705 Ph: (401) 270-6484 | Pamela Shervanick, DO 55 John A Cummings Way, Woonsocket, RI 02895-3247 Ph: (401) 235-7000 |
News Archive
Publishing online this week in Cell Host & Microbe, researchers at Johns Hopkins report the discovery of a key underlying immune mechanism that explains why to how our skin becomes inflamed from conditions such as atopic dermatitis, more commonly known as eczema. Toxin-producing bacteria on the surface of our skin induces a protein that causes our own cells to react and cause inflammation.
Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival.
The risk of relapse is significantly increased for health-care professionals treated for substance use disorders if they have coexisting psychiatric illness or a family history of substance abuse.
Eventus Diagnostics, Inc. today announced that it has received CE mark designation for its Octava Pink™ breast cancer test intended for confirmatory use in women who have received negative mammography results.
› Verified 4 days ago
Dennis Joseph Aumentado, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1065 Mendon Rd, Woonsocket, RI 02895 Phone: 401-762-0170 Fax: 401-762-3774 | |
Carolyn Sammon, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 68 Cumberland St, Suite 102, Woonsocket, RI 02895 Phone: 401-356-1940 Fax: 401-356-1949 | |
Nebyou Belay, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 55 Cummings Way, Woonsocket, RI 02895 Phone: 401-235-7000 Fax: 401-767-9107 | |
Benjamin David Lederer, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 55 John E Cummings Way, Woonsocket, RI 02895 Phone: 401-235-7021 | |
Sripriya Srinivasan, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 800 Clinton St, Woonsocket, RI 02895 Phone: 401-235-7000 Fax: 401-767-4516 | |
Jerome L Missel, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 583 Harris Ave, Woonsocket, RI 02895 Phone: 617-930-9229 | |
Penelope Anne Yanni, M.D., PH.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 68 Cumberland St, Suite102, Woonsocket, RI 02895 Phone: 401-356-1940 Fax: 401-356-1949 |